Thirty seven percent of adult male population smoke cigarettes in Qatar. The Global Youth Tobacco Survey also stated that 13.4% of male school students aged 13 to 15 years in Qatar smoke cigarettes. Smoking cessation is a key to reducing smoking related diseases and deaths. Health care providers are in an ideal position to encourage smoking cessation. Pharmacists are the most accessible health care providers and are uniquely situated to initiate behavior change among patients. Many western studies have shown that pharmacists can be successful in helping patients quit smoking. Studies demonstrating the effectiveness of pharmacist delivered smoking cessation programs are lacking in Qatar. This proposal aims to test the effect of a structured smoking cessation program delivered by trained ambulatory pharmacists in Qatar. A prospective, randomized, controlled trial will be conducted at 8 ambulatory pharmacies in Qatar. Participants will be randomly assigned to receive a 4-session face-to-face structured patient-specific smoking cessation program conducted by the pharmacist or 5 to 10 minutes of unstructured brief smoking cessation advice given by the pharmacist. Both groups will be offered nicotine therapy if feasible. The primary outcome of smoking cessation will be confirmed by exhaled carbon monoxide test at 12 months. If proven to be effective, this smoking cessation program will be considered as a model that Qatar and the region can apply to decrease smoking burden.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
314
The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies. To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability. • If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems
Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
Primary Health Corporation (PHC) pharmacies
Doha, Qatar
Qatar Petroleum pharmacies
Doha, Qatar
Self-reported 7-day Point Prevalence Abstinence
Self-reported 7-day point prevalence abstinence, defined as having smoked no cigarettes for the previous 7 days
Time frame: 3 months
Self-reported 30 Day Smoking Abstinence
Self-reported 30-day point prevalence abstinence defined as having smoked no cigarettes in the last 30 days
Time frame: 3 months
Self-reported Continuous Abstinence at 3 Months
Self-reported continuous abstinence defined as having smoked no cigarettes since quit day
Time frame: 3 months
Self-reported 7-day Point Prevalence Abstinence
Defined as having smoked no cigarettes for the previous 7 days
Time frame: 6 months
Self-reported 30-day Point Prevalence Abstinence
Defined as having smoked no cigarettes in the last 30 days
Time frame: 6 months
Self-reported Continuous Abstinence
Defined as having smoked no cigarettes since quit day
Time frame: 6 months
Self-reported 7-day Point Prevalence Abstinence
Defined as having smoked no cigarettes for the previous 7 days
Time frame: 12 months
Self-reported 30-day Point Prevalence Abstinence
Defined as having smoked no cigarettes in the last 30 days
Time frame: 12 months
Self-reported Continuous Abstinence
Defined as having smoked no cigarettes since quit day at 12 months
Time frame: 12 months
Objective Smoking Abstinence
Smoking abstinence as objectively verified by the CO exhaled test at 12 months
Time frame: 12 months
Health Related Quality of Life
Mean change in health related quality of life score from baseline to 6 months for quitters vs. non quitters
Time frame: 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.